| INTRODUCTION

Chronic Hepatitis B virus (HBV) infection affects approximately 248
million people worldwide. 1 
HBV prevalence is highest in Africa and
Eastern Asia and chronic infection will lead to death in up to 25% of those infected due to hepatocellular carcinoma (HCC) and liver cirrhosis. [1] [2] [3] In Africa, some 75 million people have chronic HBV where it is considered hyper endemic, with a seroprevalence of >8%. 2, 4, 5 In this setting, the virus is predominantly transmitted either vertically through mother to child transmission or horizontally during early childhood. 6 Current evidence regarding the geographic distribution of HBV genotypes includes that genotype D is found in North Africa, genotype E is found in Western and Central regions, and genotype
A is in Eastern and Southern regions. 5 Genotypes E and A1 are unique to Africa, except in cases where there is migration history such as slave trade or refugees.
In Australia, an estimated 218 000 people (approximately 1% of the total population) are living with chronic HBV, the majority (56%) of who were born overseas. 7 (Asia/Pacific: 38%, Europe: 10%, Africa/Middle East: 7%, Americas: 0.8%). In the past two decades, there have been increasing numbers of refugees arriving from SubSaharan Africa to Australia and also to other parts of the world. 8, 9 People from culturally and linguistically diverse (CALD) backgrounds (particularly Asia-Pacific or Sub-Saharan African background) are listed as one of the priority populations of the Australian National
Hepatitis B Strategy and as such are an important group to consider and prioritize. 10 population group. 11 Phylogenetic analysis revealed the presence of sub genotype A1 which is associated with aggressive clinical disease, 12 as well as a high prevalence of HBV variants encoding mutations in the basal core promoter (BCP) and/or precore (PC) gene associated with hepatitis B e antigen (HBeAg) negativity, with the majority of subjects having sero-converted to anti-HBe (HBeAb) despite their young age.
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The identification of BCP variants in particular is important, as recent studies have shown the presence of these mutations is associated with increased likelihood of progression to advanced liver disease, particularly cirrhosis. 13, 14 In this study, we aimed to characterize HBV isolated from adult African immigrants and refugees living in Victoria, Australia by determining the prevalence of different HBV genotypes/sub genotypes, and then performing a mutational analysis to determine the presence of clinically significant mutations and correlating them to clinical outcomes.
| MATERIALS AND METHODS
Ethics approval was received from the Royal Melbourne Hospital human research and ethics committee. to the manufacturer's instructions. Full genome amplification was carried out as previously described using HotStarTaq Plus DNA Polymerase (QIAGEN, Hilden, Germany) and primers P1 and P2 (Table 1) . 15 After purification, sequencing was performed using nine overlapping primers-SeqP1, 903, 865, 1798, 2254, JM, 2996, OSX1, and SeqP2 (Table 1) .
| Patient samples
HBV consensus sequences for the polymerase and BCP/PC genes, as well as the full genomes, were constructed using the DNA sequence analysis program SeqScape (ABI Prism, Applied Bio systems, Foster City, CA). HBV genotype and unique HBV mutations were identified using a web-based analysis program, SeqHepB, as previously described.
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| Phylogenetic analysis
The HBV polymerase sequences obtained were aligned using Clustal W and Bio edit (www.mbio.ncsu.edu/BioEdit/bioedit.html).
Consensus sequences were compared to a set of published reference sequences (GenBank) representing the 10 human HBV genotypes (A-J, approx. 50 sub genotypes) ( 
| Study population, clinical characteristics
Of the 42 patients recruited, two had insufficient viral load for amplification and subsequent genotyping and these two patients were not included in the analysis.
The clinical characteristics of the 40 patients included in the study are presented in Table 2 . Most patients were male (28, 70%), the median age was 36 years (IQR 30-45 years), and the majority (26, 65%) originated from East Africa or Horn of Africa (14 from Sudan, 6
from Somalia, 4 from Ethiopia, 2 from Eritrea, Table 2 The median viral load of all patients was 2995 IU/mL (IQR 583-34333 IU/mL). Most of the pathology results were within the normal range, and APRI score results for most of the 29 patients with available results for both platelet counts and AST lay below the threshold for increased risk for severe fibrosis or cirrhosis (Table 3) . One patient had an increased APRI score of 1.1 suggestive of cirrhosis (>1.0 indicative of cirrhosis). 19 He was a 26 year old man from Liberia, infected with HBV Genotype E, with a high viral load of 9 254 000 IU/mL, increased Only seven patients were receiving antiviral treatment (Table 3) . 
| Genotyping
Initial sequencing analysis of the 40 patients revealed 13 with genotype A (32.5%), 13 with genotype D (32.5%), and 14 with genotype E (35%). Recent reclassification of genotype A sub genotypes has grouped A3, A4, and A5 together as quasisubgenotype A3, and A6 reclassified as A4. 20 In our cohort, based on sequencing of the polymerase region, subtyping of genotype A viruses revealed 10 patients with subgenotype A1 (25%) 2 patients (5%) with quasi-subgenotype A3 and one with subgenotype A4 (2.5%) (Fig. 1) .
A recent reclassification of sub genotypes of genotype D, concluded that there are six (D1-D6) sub genotypes, not eight as previously thought. 21 The low inter-subgenotype divergence between 
| Geographic distribution
The geographic distribution of the isolated genotypes is shown in Table 2 and Fig. 2 . Twenty-six patients originated from the East African/Horn of Africa region, and these patients were infected with either genotype E, D6, D2, D/E recombinant, or A.1. 6, 8, 15, 16 The five patients from West Africa were infected with genotype E and quasisubgenotype A3. 8, 23 No genotype A1 was isolated from this region.
The five individuals from Central and Southern Africa were infected with genotype A1, A4, or E (one each). 23 Comparison of genotype distribution showed no statistically significant variation among the different regions, most likely attributable to the limited number of patients. The same patient had an sP120T mutation in the surface which is associated with HBV immunoglobulin or vaccine escape mutants.
BCP/PC sequencing was obtained for 38 patients. BCP and/or PC mutations were identified in 36/38 (95%) (Fig. 3) . Two patients did not have the classic BCP or PC mutations; however, one patient had a 1 nucleotide (nt) insertion in PC at amino acid (aa) 5 whereas the other had a 1nt deletion in PC at aa12.
| HBe serology
Serology results are shown in Table 3 : Only a minority of 3/40 patients were HBeAg positive whereas 37 were HBeAg negative. A high number of 34/37 patients with no detectable HBeAg were HBeAb positive (HBe 
| DISCUSSION
Hepatitis B is thought to have been present in Africa for thousands of years and possibly much longer. 24 The predominant genotype is thought to be A1 with probably a more recent establishment of Genotype E. 23 Genotype D is also prevalent in Northern Africa and the Middle East. Subgenotype A1 HBV encodes mutations in the BCP and PC region that decrease core protein translation and reduce HBeAg expression, 26 although the mechanism for the rapid onset of HCC in subjects infected with this strain remains unclear. 27 It was notable that no HCC occurred amongst this small sample, the majority of whom had mild liver disease and were HBeAg negative, although longitudinal follow up of these patients is required to monitor their cancer risk. Although, the high rate of HBeAg negativity observed in an African paediatric HBV population suggested the possibility of more advanced liver disease in this cohort, 11 particularly as they entered adulthood, our data demonstrated mild liver disease in the vast majority of individuals with only one case of documented cirrhosis and one of possible cirrhosis. It was notable that both these cases were Genotype E.
Consistent with this high rate of HBeAg negativity, a high incidence of BCP and/or PC mutations were observed amongst all genotypes. Mutations in these regions have been associated with increased progression to cirrhosis and/or HCC, 14,29 again supporting guidelines for early age of onset for screening in Africans with chronic HBV. The high rates of these mutations also raises the possibility that routine use of genotyping may assist in the selection of patients for treatment, as has been recommended for Asian patients with genotype B or C virus. 13 Limitations to this study include that the sample size was small and the numbers of each genotype did not allow for accurate between groups statistical comparisons. Data was also collected retrospectively, some information was incomplete and the majority of the patients were from countries in the Horn of Africa.
In conclusion, these findings have important implications for patient monitoring and treatment, particularly with increasing immigration from 
